Atec reports first quarter 2023 financial results
Carlsbad, calif.--(business wire)--alphatec holdings, inc. (nasdaq: atec), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended march 31, 2023, and recent corporate highlights. first-quarter 2023 financial results quarter ended march 31, 2023 total revenue $109 million gaap gross margin 65% non-gaap gross margin 72% gaap operating expenses $111 million non-gaap operating expenses $93 million gaap operating loss ($40) million adjusted ebitda ($5) million ending cash balance $117 million recent highlights extended momentum of ptptm (prone transpsoas) procedure, the strongest contributor to q1 revenue growth; advanced lateral sophistication with full commercial release of ltptm (lateral transpsoas) procedure; introduced atec ais (adolescent idiopathic scoliosis) approach, with adaptable invictustm instrumentation designed to streamline and optimize de-rotation; drove 40% increase in surgical volume and 11% increase in average revenue per procedure; acquired navigation-enabled robotics platform to enhance precision of atec’s procedural strategy. “we continue to execute against our mission to revolutionize the approach to spine surgery,” said pat miles, chairman and chief executive officer. “as many in our industry capitulate, or seek to drive growth through acquired revenues, atec is content to be the outlier: methodically applying our 100% spine focus and unmatched know-how to integrate and evolve technologies that improve the predictability and reproducibility of spine care. atec's innovation is not only driving rapid adoption today, it will also set new clinical standards for years to come.” financial outlook for the full-year 2023 the company continues to expect total revenue to grow 28% to $450 million for the fiscal year ended december 31, 2023, in line with expectations shared in conjunction with the release of preliminary first-quarter financial results. this includes surgical revenue growth of approximately 30% and $57 million of eos revenue. the company continues to expect to achieve non-gaap adjusted ebitda break-even for the full-year 2023. financial results webcast atec will present these results via a live webcast today at 1:30 p.m. pt / 4:30 p.m. et. the live webcast can be accessed by visiting the investor relations section of atec’s corporate website. to dial in to the webcast, please register via this link. a replay of the webcast will remain available through the investor relations section of atec’s corporate website for twelve months. in addition, a dial-in replay will be available beginning about two hours after the webcast’s completion through may 11, 2022. access the replay by dialing (800) 770-2030 and referencing conference id number 97241. non-gaap financial information to supplement the company’s financial statements presented in accordance with generally accepted accounting principles in the united states of america (gaap), the company reports certain non-gaap financial measures, including non-gaap gross margin, non-gaap operating expenses, non-gaap operating loss, and non-gaap adjusted ebitda. the company believes that these non-gaap financial measures provide investors with an additional tool for evaluating the company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the company. the company’s non-gaap financial measures may not provide information that is directly comparable to that provided by other companies in the company’s industry, as other companies in the industry may calculate non-gaap financial results differently, particularly related to non-recurring, unusual items. non-gaap financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with gaap. included below are reconciliations of the non-gaap financial measures to the comparable gaap financial measures. about alphatec holdings, inc. atec, through its wholly owned subsidiaries, alphatec spine, inc., eos imaging s.a. and safeop surgical, inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. atec’s organic innovation machinetm is focused on developing new approaches that integrate seamlessly with the company’s expanding alphainformatix platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. atec’s vision is to be the standard bearer in spine. for more information, visit us at www.atecspine.com. forward looking statements this press release contains "forward-looking statements" within the meaning of the private securities litigation reform act of 1995 that involve risks and uncertainty. such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. the company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. forward-looking statements include, but are not limited to: references to the company’s revenue, balance sheet, growth and financial outlook; planned product launches and introductions; and the company’s ability to compel surgeon adoption. important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the company’s ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the company’s products by the surgeon community; failure to obtain fda or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable first-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the company’s ability to achieve profitability; uncertainty of additional funding; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the company’s intellectual property; and the company’s ability to meet its financial obligations. a further list and description of these and other factors, risks and uncertainties can be found in the company's most recent annual report, and any subsequent quarterly and current reports, filed with the securities and exchange commission. atec disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. alphatec holdings, inc. condensed consolidated statements of operations (in thousands, except per share amounts) three months ended march 31, 2023 2022 $ 109,110 $ 70,918 — 15 109,110 70,933 38,685 21,717 70,425 49,216 13,260 9,722 91,262 69,471 3,192 7,532 2,883 2,230 — 120 175 1,370 110,772 90,445 (40,347 ) (41,229 ) (3,874 ) (1,456 ) 706 (30 ) (3,168 ) (1,486 ) (43,515 ) (42,715 ) 14 (99 ) $ (43,529 ) $ (42,616 ) $ (0.40 ) $ (0.43 ) 109,751 99,978 $ 6,006 $ 256 1,317 972 9,139 8,956 $ 16,462 $ 10,184 (unaudited) $ 116,698 $ 84,696 62,415 60,060 108,242 101,521 11,798 9,357 299,153 255,634 109,750 101,952 28,063 28,360 47,924 47,367 81,079 82,781 3,724 4,874 $ 569,693 $ 520,968 $ 39,070 $ 34,742 69,032 72,382 13,938 11,956 16,068 14,948 4,796 4,842 142,904 138,870 461,548 393,162 23,603 23,603 (58,362 ) (34,667 ) $ 569,693 $ 520,968 2023 2022 $ 70,425 $ 49,216 220 - 6,006 256 195 - 2,098 1,706 $ 78,944 $ 51,178 64.5 % 69.4 % 0.2 % 0.0 % 5.5 % 0.4 % 0.2 % 0.0 % 1.9 % 2.4 % 72.3 % 72.1 % 2023 2022 $ 110,772 $ 90,445 (10,456 ) (9,928 ) (3,192 ) (7,532 ) (2,883 ) (2,230 ) - (120 ) (175 ) (1,370 ) (1,349 ) - $ 92,717 $ 69,265 2023 2022 $ (40,347 ) $ (41,229 ) 8,589 7,085 3,103 2,230 (28,655 ) (31,914 ) 16,462 10,184 195 - 2,098 1,706 3,192 7,532 - 120 175 1,370 1,349 - $ (5,184 ) $ (11,002 ) 1
